The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
24296Cm + 42He → 24598Cf + 10n To identify and separate out the element, ion exchange and adsorption methods were undertaken. Only about 5,000 atoms of californium were produced in this experiment, and these atoms had a half-life of 44 minutes. The discoverers named the new element after the university and the state. This was a break from the convention used for elements 95 to 97, which drew inspiration from how the elements directly above them in the periodic table were named. However, the element directly above element 98 in the periodic table, dysprosium, has a name that means "hard to get at", so the researchers decided to set aside the informal naming convention. They added that "the best we can do is to point out [that] ... searchers a century ago found it difficult to get to California". Weighable amounts of californium were first produced by the irradiation of plutonium targets at Materials Testing Reactor at National Reactor Testing Station, eastern Idaho; these findings were reported in 1954. The high spontaneous fission rate of californium-252 was observed in these samples. The first experiment with californium in concentrated form occurred in 1958. The isotopes 249Cf to 252Cf were isolated that same year from a sample of plutonium-239 that had been irradiated with neutrons in a nuclear reactor for five years.
== Patient population == The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health risks to justify the use of anti-obesity medication. The American Academy of Pediatrics had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023, which recommend considering the use of weight loss medication in some overweight children aged 12 or older. The European Medicines Agency has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least 60 kilograms (130 lb). However, GLP-1 agonists may not be cost effective in this population.
=== Opposable thumbs === Opposable thumbs allowing the grasping of objects are most often associated with primates, like humans and other apes, monkeys, and lemurs. Opposable thumbs also evolved in giant pandas, but these are completely different in structure, having six fingers including the thumb, which develops from a wrist bone entirely separately from other fingers.
=== Equilibria involving gases === When dealing with gases, fugacity, f, is used rather than activity. However, whereas activity is dimensionless, fugacity has the dimension of pressure. A consequence is that chemical potential has to be defined in terms of a standard pressure, po:
Sources: en.wikipedia.org
=== InPen === The InPen is a reusable, bluetooth-enabled insulin pen, manufactured by Medtronic, that can connect to Dexcom CGM systems. The InPen can connect to the G6 and G7 through the InPen app, the Apple iPhone's Heath app, and on the Apple Watch.
The adenosine nucleotide binding site is located between two beta hairpin-shaped structures pertaining to the I and III domains. The residues that are involved are Asp11-Lys18 and Asp154-His161 respectively. The divalent cation binding site is located just below that for the adenosine nucleotide. In vivo it is most often formed by Mg2+ or Ca2+ while in vitro it is formed by a chelating structure made up of Lys18 and two oxygens from the nucleotide's α-and β-phosphates. This calcium is coordinated with six water molecules that are retained by the amino acids Asp11, Asp154, and Gln137. They form a complex with the nucleotide that restricts the movements of the so-called "hinge" region, located between residues 137 and 144. This maintains the native form of the protein until its withdrawal denatures the actin monomer. This region is also important because it determines whether the protein's cleft is in the "open" or "closed" conformation. It is highly likely that there are at least three other centres with a lesser affinity (intermediate) and still others with a low affinity for divalent cations. It has been suggested that these centres may play a role in the polymerization of actin by acting during the activation stage. There is a structure in subdomain 2 that is called the "D-loop" because it binds with DNase I, it is located between the His40 and Gly48 residues. It has the appearance of a disorderly element in the majority of crystals, but it looks like a β-sheet when it is complexed with DNase I.
Latin American leaders, including the presidents of Colombia, Guatemala and Mexico, have called for debate about legalizing and regulating aspects of drug production, trade or use. Some Latin leaders are discussing the need to experiment further with decriminalizing possession of drugs. Lawmakers are also proposing to scrap jail terms for growing coca and cannabis. As some Latin American leaders call for legalization of narcotics, Peru, a leading coca grower, remains opposed.
Sources: en.wikipedia.org
== Titanium-44 == Titanium-44 (44Ti) is a radioactive isotope of titanium that undergoes electron capture with a half-life of 59.1 years to an excited state of scandium-44, before reaching the ground state of 44Sc and ultimately of 44Ca. Because titanium-44 can decay only through electron capture, its half-life increases slowly with its ionization state and it becomes stable in its fully ionized state (that is, having a charge of +22), though as astrophysical environments never lack electrons completely, it will always decay. Titanium-44 is produced in relative abundance in the alpha process in stellar nucleosynthesis and the early stages of supernova explosions. It is produced when stable calcium-40 adds an alpha particle (helium-4), as nickel-56 is the result of adding three more. The age of supernova remnants (even though nickel-56 has died away to iron) may be determined through measurements of gamma-ray emissions from the relatively long-lived titanium-44 and of its abundance. It was observed in the Cassiopeia A supernova remnant and SN 1987A at a relatively high concentration, enhanced by the delayed decay in the ionizing conditions.
==== Australia ==== Taco Bell first opened in Australia in September 1981, but Taco Bell was ordered to change its name after the owner of a local restaurant successfully sued Taco Bell for misleading conduct. The local restaurant was called "Taco Bell's Casa" and had been operating in Australia since the 1970s. The owner successfully argued that Sydneysiders would confuse the takeaway chain with his restaurant, and this would damage his reputation. Taco Bell later opened in 1997 in Australia with a store in the cinema district on George Street, Sydney and a year later in 1998 within a few KFC stores in the state of New South Wales, but by 2005, the Taco Bell brand was pulled out of the country. On September 13, 2017, Collins Foods announced that Taco Bell would return to the Australian market, with their first store being situated in the Brisbane suburb of Annerley in Queensland using a refurbished Sizzler restaurant which had closed earlier that year. The Annerley store opened on November 4, 2017. In 2018, Collins Foods signed a development deal with Yum! Brands to open over 50 Taco Bell restaurants across Australia between January 2019 and December 2021. A legal dispute with Victoria-based restaurant chain Taco Bill was resolved in February 2020. As of February 2024, there are 39 Taco Bell restaurants across Australia; 12 in New South Wales, 13 in Queensland, nine in Victoria, and four in Western Australia. There are also plans to open restaurants in other locations, such as Canberra, the Central Coast, Port Macquarie and Toowoomba.
== Medical significance == Pathogenic (homozygous and compound heterozygous) mutations in TARS1 are associated with trichothiodystrophy (a type of hair fragility disorder), with the type caused by TARS1 mutation designated as: nonphotosensitive trichothiodystrophy-7 (TTD7).
13C + n → 14C In this case the atomic mass increases, but the element is unchanged. In other cases the product nucleus is unstable and decays, typically emitting protons, electrons (beta particle) or alpha particles. When a nucleus loses a proton the atomic number decreases by 1. For example,
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.